All In Biotech

Drug Trial Radar · NCT03594890

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.

Last checked: Nov 19, 2026Latest source record: Sep 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jun 12, 2018

Primary completion

Aug 7, 2019

Study completion Aug 7, 2019

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
Aepodia
First posted
Jul 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.

Conditions

  • Influenza

Interventions

  • OVX836 (Intramuscular)Biological

    2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.

  • Placebo (Intramuscular)Biological

    2 consecutive administrations of placebo at Day 1 and Day 29.

  • OVX836 (Intranasal)Biological

    2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.

  • Placebo (Intranasal)Biological

    2 consecutive administrations of placebo at Day 1 and Day 29.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Out-of-Range Safety Lab dataTime frame: 28 days after last vaccine administration.
  2. Safety: Solicited local and systemic reactionsTime frame: 7 days after last vaccine administration.
  3. Safety: Unsolicited Adverse EventsTime frame: 28 days after last vaccine administration.
  4. Safety: Serious Adverse EventsTime frame: at end of study visit (i.e. Week 22)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for the Evaluation of Vaccination, University of Antwerp

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.